KR20160137035A - A composition of plants extract for treating atopic dermatitis - Google Patents

A composition of plants extract for treating atopic dermatitis Download PDF

Info

Publication number
KR20160137035A
KR20160137035A KR1020150071539A KR20150071539A KR20160137035A KR 20160137035 A KR20160137035 A KR 20160137035A KR 1020150071539 A KR1020150071539 A KR 1020150071539A KR 20150071539 A KR20150071539 A KR 20150071539A KR 20160137035 A KR20160137035 A KR 20160137035A
Authority
KR
South Korea
Prior art keywords
atopic dermatitis
skin
composition
extract
formulation example
Prior art date
Application number
KR1020150071539A
Other languages
Korean (ko)
Inventor
황은주
Original Assignee
주식회사 더삼점영
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 더삼점영 filed Critical 주식회사 더삼점영
Priority to KR1020150071539A priority Critical patent/KR20160137035A/en
Publication of KR20160137035A publication Critical patent/KR20160137035A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The production of epidermal protein, filaggrin, significantly decreases in the skin of atopic dermatitis patients and this decrease directly causes dehydration of stratum corneum. The present invention relates to a cosmetic composition comprising a material obtained from a natural extract that activates gene expression of the protein, filaggrin, which can cause defects in the skin barrier.

Description

아토피 피부염증 치료용 식물추출 조성물 {A composition of plants extract for treating atopic dermatitis}[0001] The present invention relates to a plant extract for treating atopic skin inflammation,

본 발명은 피부장벽의 구성단백질 Filaggrin 유전자의 발현을 활성화 시키는 아토피 피부염증 완화용 화장료 조성물에 관한 것이다.
The present invention relates to a cosmetic composition for relieving atopic skin inflammation that activates the expression of the filaggrin gene constituting the skin barrier.

아토피 피부염은 근래에 환경오염과 함께 환자가 전 세계적으로 크게 증가하는 만성질병이다. 아토피 피부염치료는 최근에야 그 근본적인 원인이 밝혀지게 되면서 치료를 더욱 효과적으로 할 수 있는 여러 방법의 접근이 가능하게 되었다. 아토피 피부염증을 근본적으로 치유하는 치료제의 개발은 경쟁이 갈수록 치열해지고 있으며 우수한 치료제는 국내는 물론 전 세계적인 큰 시장을 가지고 있기 때문에 국가 경제에 큰 이익을 가져올 연구 분야이다.
Atopic dermatitis is a chronic disease in which the patient is increasing worldwide in recent years with environmental pollution. The treatment of atopic dermatitis has only recently become known, and various approaches have been made to make treatment more effective. The development of therapeutic agents that essentially cure atopic skin inflammation is becoming more and more intensified, and excellent therapeutic products are a field of study that will bring great benefits to the national economy because it has a large market both domestically and globally.

아토피 피부염에서 각질층의 투과장벽의 비정상성(Permeability barrier abnormality)은 단순한 현상보다 병의 활성을 유발하는 근본 원인으로 밝혀지고 있다. 연구자들은 비정상적인 침투장벽의 정도의 세기에 따라 아토피 피부염의 병적인 심각한 증상과 평행으로 깊은 관계를 가지게 됨을 알아냈다.
Permeability barrier abnormality of stratum corneum in atopic dermatitis has been found to be the root cause of disease activity rather than simple phenomenon. The researchers found that the severity of abnormal infiltration barriers has a profound parallel relationship with the pathological severe symptoms of atopic dermatitis.

또 아토피 피부염 환자의 선천적인 피부 표피를 구성하는 단백질인 필라그린(Filaggrin), 인볼류신(Involucin), Cysteine A and Tad-H-1 항체 등의 단백질이 정략적으로 상실 생성되어 얻어지는 질병이다. 그리고 이들 대사물질은 삼투물질로 기능하여 물이 각질층으로 유입되면서 각질층 표면의 수분공급의 감소로 나타난다. 대신 기질층을 따라 경사진 물 농도차이를 형성 물 손실이 증가하여 표피가 건조하게 된다. 각질층 물 공급의 감소는 증가된 물손실로 Filaggrin(Filamet Aggregating Protein) 단백질 유전자의 발현이 현저하게 감소되므로 아토피 피부염의 가장 첫 번째로, 분명한 장벽 생성의 장애의 원인이 된다.
In addition, it is a disease that is obtained by the loss of the proteins such as filaggrin, Involucin, Cysteine A and Tad-H-1 antibodies which are proteins of the innate skin epidermis of atopic dermatitis patients. These metabolites function as an osmotic material, resulting in a decrease in water supply to the stratum corneum surface as water enters the stratum corneum. Instead, it forms a sloping water concentration difference along the substrate layer, resulting in increased water loss and drying of the epidermis. The reduction of the stratum corneum water supply is the first of the atopic dermatitis because of the marked decrease in the expression of the filaggrin (filament aggre- gating protein) protein gene due to the increased water loss.

아토피 피부염은 현재 다양한 화학제품의 사용으로 일반화 된 질병으로 출생하여 11살까지의 환자의 증가가 뚜렷하고, 성장하면서 증상이 누그러지기도 한다. 하지만 이 질병은 성인이 되어서도 발병하기도 하여 심각한 핸디캡으로 작용하며 삶의 질에 지대한 영향을 주기도 한다. 일반적으로 병원에서 하는 처치방법으로 자극되는 물질은 피하고 수시로 보습제를 사용해야하며, 국부적으로는 Corticosteroid를 사용하도록 한다. 증상이 극도로 심한 경우 자외선B(UVB)의 조사나 경구 투여하는 psorlen 의 투여로 광화학치료를 시행한다. 이러한 처치에도 효과가 없으면, 입원하여 체계적인 코티코스테로이드나 사이클로스포린을 투여하는 치료가 수행된다.
Atopic dermatitis is a common disease caused by the use of various chemical products, and the increase in the number of patients until the age of 11 is apparent, and the symptoms may be alleviated by growing. However, this disease can also be caused by an adult, which acts as a serious handicap and has a profound effect on the quality of life. Generally, you should avoid the stimulants that are used in hospitals and use moisturizers from time to time, and use Corticosteroid locally. If the symptoms are extremely severe, photochemical therapy should be performed with ultraviolet B (UVB) irradiation or oral administration of psorlen. If this treatment is not effective, treatment is administered to the patient by systemic corticosteroids or cyclosporine.

아토피성 피부염증에는 가려움증이 가장 환자에게 고통을 준다. 실제로 가려움증 치료제로는 코티코스테로이드제, 항히스타민제. 면역억제제, 캡사이신 등이 사용되나 이 치료제들은 나름대로 부작용을 가지고 있다. 바르는 스테로이드제에 의해서는 피부가 얇아지거나 피부 색깔이 변하거나 발진이 생기고, 장기간 많은 양을 사용했을 때 전신 부작용으로 부신 기능이 억제될 수 있다. 또한 아토피성 피부염에 국소 항히스타민제의 사용은 권장되지 않고 있는데, 이것은 피부 과민반응의 위험이 있기 때문이다. 진정작용이 없는 2 세대 항히스타민제 에바스틴과 터페나딘은 사이토크롬(cytochrome) P450 활성을 저해하는 약물 (ketoconazole, erythromycin)과 함께 복용하면 부정맥을 일으킬 수 있다(Hey et al., Arzneimittelforschung, 46, pp159-163, 1996).
In atopic skin inflammation, itching is the most painful patient. In fact, itching medicines include corticosteroids, antihistamines. Immunosuppressants, and capsaicin are used, but these drugs have side effects in their own way. Adequate steroids can cause skin thinning, skin color change, or rash, and adverse effects can be suppressed by systemic side effects when used in large amounts over a long period of time. Also, the use of topical antihistamines for atopic dermatitis is not recommended because of the risk of skin sensitization. Second-generation antihistamines without sedation Evastin and terfenadine can cause arrhythmias when taken with ketoconazole, erythromycin (Hey et al., Arzneimittelforschung, 46, pp159 -163, 1996).

면역억제제인 사이클로스포린(cyclosporine)은 전신투여 시 고혈압, 신독성, 약물 상호 작용 등의 심각한 부작용을 초래할 수 있고 분자량이 커서 장기를 통과하여 피부에 이르기가 어려워 효능이 약하다. 최근 국소 제제로 개발된 칼시뉴린 억제제인 프로토픽(타크로리무스, FK506)과 엘리델(피메크로리무스)은 소아환자에서 백혈병 발병률을 증가시키는 것으로 밝혀지고 있고, 더 나아가 사용 초기에 피부자극, 가려움 홍반 등의 부작용이 보고되고 있다(Gupta et al., JEADV, 16, pp.100-114, 2002; Gupta and Chow, JEADV, 17, pp.493-503, 2003). 이렇게 현재 임상적으로 사용되는 약물은 상당히 큰 부작용을 가지고 있기 때문에 약효가 뛰어나고 부작용이 전혀 없는 아토피성 피부염 치료제의 개발이 시급한 상태이다.
Cyclosporine, an immunosuppressant, can cause severe side effects such as hypertension, nephrotoxicity, and drug interactions when administered systemically, and its efficacy is poor due to its high molecular weight and difficulty in reaching the skin through the organs. Recently, protincip (tacrolimus, FK506) and alldel (pimecrolimus), a calcineurin inhibitor developed in topical formulations, have been shown to increase the incidence of leukemia in pediatric patients and, furthermore, (Gupta et al., JEADV, 16, pp. 100-114, 2002; Gupta and Chow, JEADV, 17, pp. 493-503, 2003). Currently, the currently used drugs have considerable side effects, so it is urgent to develop a therapeutic agent for atopic dermatitis, which has excellent efficacy and no side effects.

본 발명에서 부작용이 거의 없으며 약효가 특별히 우수한 약물을 찾아내기 위하여 아토피 피부염의 가장 큰 원인으로 알려진, 현저하게 감소한 세포벽 형성의 주요 단백질인 Filaggrin 유전자의 발현을 활성화 시키는 물질들을 얻어내는 연구를 수행하였다. 그 결과 아토피성 피부염에 탁월한 효과가 있는 대회향, 맥문동, 천초근, 황금, 감초의 추출물을 함유하는 혼합물을 발명하였다. In order to find a medicinal drug having little side effects and little side effects in the present invention, a study was conducted to obtain substances that activate the expression of the filaggrin gene, which is a major protein of the cell wall formation, which is known to be the major cause of atopic dermatitis. As a result, we have invented a mixture containing extracts of mackumundo, chaetong root, golden, licorice, which have excellent effects on atopic dermatitis.

본 발명이 해결하고자 하는 기술적 과제는 아토피성피부염 완화용 식물추출 조성물을 제공하는 것이다.
The present invention provides a plant extract composition for alleviating atopic dermatitis.

Filaggrin의 배양된 각질세포에서 발현의 정도는 western blot으로 사람의 Anti-Filaggrin antibody를 사용하여 측정하였다.
The degree of expression in cultured keratinocytes of Filaggrin was measured by Western blot using human anti-filaggrin antibody.

세포의 배양은 사람의 keratinocyte(Welskin, Seoul)는 회사에서 제공한 성장보충제화 성장배지에서 배양하였다.
Cultures of cells were cultured in growth supplemented growth medium supplied by the company with human keratinocyte (Welskin, Seoul).

단백질추출은 식물추출물을 포함하지 않은 배지의 배양세포와 식물추출물을 포함시킨 배양액에서 성장한 세포를 PBS(Phosphate Buffered Saline)으로 세척한 다음 Pro-PREP Protein Extraction solution(iNtRON, Biotechnology, Seoul)에 용해시켰다.
For protein extraction, the cells grown in culture medium containing plant extracts and plant extract-free medium were washed with PBS (Phosphate Buffered Saline) and dissolved in Pro-PREP Protein Extraction solution (iNtRON, Biotechnology, Seoul) .

Western-blot test는 세포 용해물의 일부를 SDS-polyacrylamide gel에서 전기영동 시킨 후 Hybond-p* polyvinylidene fluoride membrane(Amersham Biosciences, U. K.)로 옮겼다. Filaggrin 단일 클론 항체(형광표지)를 사용하여 단백질을 검출하였다.
Western blotting was performed by transferring a portion of the cell lysate to a Hybond-p * polyvinylidene fluoride membrane (Amersham Biosciences, UK) after electrophoresis on SDS-polyacrylamide gel. Proteins were detected using a Filaggrin monoclonal antibody (fluorescent label).

식물추출물은 75% MeOH를 사용하여 50에서 추출한 후 감압여과로 추출액을 회수 하였다.
The extracts were extracted with 50% MeOH at 50%, and the extracts were recovered by vacuum filtration.

본 발명의 아토피성피부염 완화용 식물추출 조성물은 총중량에 대하여 대회향 추출물 5~10%, 맥문동, 천초근 각 2.5~5%, 황금, 감초의 추추출물 각 3~7%일 수 있다. 상기 중량범위에서 아토피성피부염증 완화에 효과가 탁월하며 사용자의 만족도가 증가한다.
The plant extract composition for alleviating atopic dermatitis according to the present invention may contain 5 ~ 10% of the extract of the oriental herb, 2.5 ~ 5% of the root extract, 3 ~ 7% of the extract of the golden and licorice root, respectively. In the above weight range, the effect on relieving atopic skin irritation is excellent and user satisfaction is increased.

위 추출물 오일이 포함된 것은 혼합하기 위해 에탄올 등의 용매를 사용할 수 있다.
A solvent such as ethanol may be used for mixing with the above extract oil.

아토피 피부염 완화에 사용하기 위한 발명의 추출물의 약학적 투여 형태는 외용제에 한정된다. 즉, 주사제나 경구 투여형 제제는 제외된다. 바람직하게는 스프레이제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용제 등을 들 수 있다. The pharmaceutical dosage form of the extract of the invention for use in relieving atopic dermatitis is limited to external preparations. In other words, injections and oral dosage forms are excluded. Preferred examples thereof include a spray, an ointment, a warning agent, a lotion, a liniment, a pasta agent or a cataplasma external preparation for skin.

본 발명의 식물추출 조성물은 아토피 피부염 증상 완화효과가 뛰어나며, 사용자의 만족도가 크다는 장점을 갖는다.The plant extract composition of the present invention has an excellent effect of alleviating symptoms of atopic dermatitis, and has an advantage of high satisfaction of the user.

이하, 본 발명에 대해서 제제예, 실시예를 통하여 더욱 상세히 설명한다. 그러나, 이는 본 발명을 설명하기 위한 것이며, 본 발명이 이들 실시예에 의해 제한되는 것은 아니다.
Hereinafter, the present invention will be described in more detail through formulation examples and examples. However, this is for the purpose of illustrating the present invention, and the present invention is not limited by these examples.

<제제예 1>
<Formulation Example 1>

비교제제예 1~5에서 준비된 대회향, 맥문동, 천초근, 황금, 감초의 추출물을 표 1에 기재된 조성으로, 비교제제예 1~5의 연고제 제조 방식으로 연고제를 제조하였다.
An ointment preparation was prepared in the same manner as in Comparative Preparation Examples 1 to 5, except that the extracts prepared in Comparative Preparation Examples 1 to 5, extracts of ginseng root, ginseng root, ginseng, and licorice were prepared as shown in Table 1.

구분division 대회향Conversation 맥문동McMundong 천초근Chunkyong 황금Gold 감초licorice 바세린Vaseline 비교제제예 1Comparative Formulation Example 1 33 4.54.5 4.54.5 77 77 7474 비교제제예 2Comparative Formulation Example 2 66 3.53.5 3.53.5 6.56.5 6.56.5 7474 비교제제예 3Comparative Formulation Example 3 99 2.52.5 2.52.5 66 66 7474 비교제제예 4Comparative Formulation Example 4 1212 2.52.5 2.52.5 4.54.5 4.54.5 7474 비교제제예 5Comparative Formulation Example 5 1515 2.52.5 2.52.5 33 33 7474 제제예 1Formulation Example 1 1010 55 55 33 33 7474

<실시예 1> 아토피 피부염증 완화 효과 확인
Example 1 Confirmation of Atopic Skin Irritation Mitigation Effect

아토피 피부염증 완화 효과 확인시험을 이하의 방법으로 하였다.
Atopic skin inflammation mitigation efficacy test was performed by the following method.

새로 지은 아파트에 입주한 거주자 중에서 아토피 피부염증 환자를 모집하여, 심한 가려움증을 지각하여 1분에 1회 이상 긁는 상태에 있는 총 50명의 사람을 시험대상으로 선정하였으며, 한 군당 10명씩 총 5개 군으로 나누었다. 각각의 군에 대하여, 비교제제예 1 내지 5와 제제예 1의 연고제를 시료로 사용하였다. 피검자 각자에게 긁는 부위 중 한 곳에는 비교제제예 1 내지 5의 연고제를 도포하도록 하였고, 다른 한 곳에는 제제예 1의 연고제를 도포하도록 하였다. 사용량은 각각 0.1~0.3ml의 양을 도포하도록 하였다. 피검자에게 1분 후, 10분 후, 1시간 후의 가려움이 있는지를 질문하여 답을 구하였으며, 가려움을 느낀 사람의 수를 표 2에 나타내었다. 가려움의 정의는 가려운 부위에 손이 2번 이상 간 상태로 정의하였다.
A total of 50 people who were scratching at least once a minute were recruited from the residents of the newly built apartment. The subjects were divided into 5 groups Respectively. For each group, the ointments of Comparative Preparation Examples 1 to 5 and Preparation Example 1 were used as samples. One of the scratching areas of Comparative Examples 1 to 5 was applied to each of the test subjects, and the ointment of Formulation Example 1 was applied to the other portion. The amount of 0.1 to 0.3 ml was applied. The subjects were asked whether they had itching after 1 minute, 10 minutes, and 1 hour, and the number of people who felt itching was shown in Table 2. The definition of itching is defined as the condition where the hand has gone two or more times on the itchy area.

구분division 1분 후
가려움증인원/피검인원
(비율%)After 1 minute
Itching person / examinee
(ratio%) 10분 후
가려움증인원/피검인원
(비율%)After 10 minutes
Itching person / examinee
(ratio%) 1시간 후
가려움증인원/피검인원
(비율%)After 1 hour
Itching person / examinee
(ratio%) 비교제제예 1Comparative Formulation Example 1 8/10(80%)8/10 (80%) 7/10(70%)7/10 (70%) 7/10(70%)7/10 (70%) 비교제제예 2Comparative Formulation Example 2 6/10(60%)6/10 (60%) 7/10(70%)7/10 (70%) 6/10(60%)6/10 (60%) 비교제제예 3Comparative Formulation Example 3 8/10(80%)8/10 (80%) 7/10(70%)7/10 (70%) 7/10(70%)7/10 (70%) 비교제제예 4Comparative Formulation Example 4 6/10(60%)6/10 (60%) 5/10(50%)5/10 (50%) 4/10(40%)4/10 (40%) 비교제제예 5Comparative Formulation Example 5 8/10(80%)8/10 (80%) 7/10(70%)7/10 (70%) 7/10(80%)7/10 (80%) 제제예 1Formulation Example 1 15/50(30%)15/50 (30%) 12/50(24%)12/50 (24%) 8/50(16%)8/50 (16%)

상기 표 2에 나타난 시험의 결과는 다음과 같은 사실을 나타낸다. 첫째, 대회향을 적게 포함한 비교제제예 1, 2는 아토피 피부염증 완화에 효과가 크지 않음을 나타낸다. 둘째, 시간의 경과는 아토피 피부염에 기인하는 소양증완화의 깊은 관련이 있음을 알 수 있다. 마지막으로 대회향, 맥문동, 천초근, 감초, 대회향의 출물의 혼합제제가 아토피 피부염 증상 완화에 50% 정도의 효과가 있음을 나타내고 있다.
The results of the tests shown in Table 2 above indicate the following facts. First, comparative preparations Examples 1 and 2, which contain fewer synergistic effects, are not effective at alleviating atopic skin inflammation. Second, the lapse of time is related to the attenuation of pruritus caused by atopic dermatitis. Finally, it is shown that the combination of shiitake mackerel, mackumundong, chaetong root, licorice, and decaffeinated extract has a 50% effect on relieving atopic dermatitis symptoms.

따라서, 본 발명의 조성물의 아토피 피부염 완화 효과가 뛰어남을 알 수 있다.
Therefore, it can be seen that the composition of the present invention is excellent in the effect of alleviating atopic dermatitis.

<시험예 1> 피부자극성 확인 인체피부첩포시험
&Lt; Test Example 1 > Confirming skin irritation Human skin patch test

아토피 피부염증 완화용 식물추출 조성물의 피부자극성의 정도를 확인하기 위해 인체 피부첩포 시험을 하였다. 과거력상 피부자극에 과민반응을 보인 적이 없으며, 현재 피부병 내지 피부 알러지 증상이 없는 피검자 20명을 대상으로 하였다. 피검자의 연령 분포는 20-35세이며, 평균 연령은 31세였다.
In order to confirm the degree of skin irritation of a plant extract composition for relieving atopic skin inflammation, a human skin patch test was conducted. Twenty patients who had never been hypersensitive to skin irritation due to a history of the disease and who currently have no skin disease or skin allergy symptoms were included. The age distribution of the subjects was 20-35 years, and the average age was 31 years.

시험방법은 아래와 같다. 우선 시험부위를 70% 에틸알코올로 닦아낸 뒤 건조시켰다. 실시예 1의 조성물 3종 각각을 종이 디스크에 40씩 묻혀서, 이를 스켄포어 테잎(scanpore tape)으로 등 부위의 피부에 고정시키고, 24시간 후 첩포를 떼어낸 표시펜으로 시험부위를 표시하였다. 그 뒤 4시간 후 결과를 육안으로 판정하였다. 결과는 홍반과 부종의 정도에 따라 수치로 나타내며, 판정기준은 국제접촉피부염 연구위원회 (International Contact Dermatitis Research Group;ICDRG)의 기준에 따랐다.(Wooding et al. 1967; Rietschell, 1982; Fischer & Maibach, 1984; Aberer et al, 1993). (피부반응평가기준: 0점(무반응), 0.5점(희미한 또는 가벼운 홍반), 1점(경계가 뚜력하나 약한 홍반, 부종 및 구진), 2점(뚜렷한 홍반, 구진 및 소수포), 3점(심한 홍반 및 대수포, 가피형성))
The test method is as follows. First, the test area was wiped with 70% ethyl alcohol and dried. Each of the three compositions of Example 1 was put on a paper disc for 40 times, fixed on the skin of the back area with a scanpore tape, and the test area was marked with a display pen from which the patch was removed after 24 hours. After 4 hours, the results were visually judged. The results were based on the degree of erythema and edema, and the criteria were based on the criteria of the International Contact Dermatitis Research Group (ICDRG) (Wooding et al., 1967; Rietschell, 1982; Fischer & Maibach, 1984; Aberer et al, 1993). (Skin reaction evaluation criteria: 0 point (no reaction), 0.5 point (faint or mild erythema), 1 point (border eruption weak erythema, edema and papule), 2 points (marked erythema, (Severe erythema and alveoli, scab formation))

하기 수학식에 의하여 평균 피부 반응도를 계산하고 그 결과를 표에 나타내었다.The average skin reactivity was calculated by the following formula and the results are shown in the table.

수학식 1Equation 1

평균 피부 반응도(mean score)=(0점무반응 인원수 + 0.5점해당반응인원수 + 1점해당반응인원수 + 2점해당반응인원수 + 3점해당반응인원수)/최대점수(3)총피검자수(20))100
Mean score = (0 score of the number of reactions + 0.5 points of the respondents + 1 point of the respondents + 2 points of the respondents + 3 points of the respondents) / maximum score (3) ) 100

평균피부반응도(n=20)Mean skin response (n = 20) 비교제제예 1Comparative Formulation Example 1 2525 비교제제예 4Comparative Formulation Example 4 00 제제예 1Formulation Example 1 00

표 3에서 보는 바와 같이 조성물에 포함하는 제제예1과 비교제제예 4은 피부자극성이 거의 없는 것으로 나타난 반면, 적은 양의 대회향을 포함하는 비교제제예 1의 경우 도포부위의 경계가 확연하게 나타나고 약한 홍반이 관찰되었다. 결과적으로, 본 발명의 조성물에 의한 피부자극을 피하기 위해선 대회향이 일정 정도 이상 포함되어야한다는 사실을 확인하였다.
As shown in Table 3, Formulation Example 1 and Comparative Formulation Example 4 included in the composition showed little irritation to the skin, whereas Comparative Example Example 1, which contained a small amount of the lotion, Erythema was observed. As a result, it was confirmed that to avoid skin irritation by the composition of the present invention, the incense of the tournament should be more than a certain degree.

Claims (2)

대회향, 맥문동, 천초근, 황금, 감초의 추출물에서 얻은 효소활성제의 제재로 아토피성 피부염증 완화에 효과를 갖는 추출조성물
Extract composition having effect on alleviating atopic skin inflammation by using enzyme active agent obtained from extract of mackerel, mackumundo, chunghwa root, golden, licorice extract
제1항에 있어서 상기 조성물의 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 클렌징, 파운데이션 중에서 선택된 제형을 갖는 식물추출조성물

The plant extract composition according to claim 1, having a formulation selected from a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a cleansing and a foundation of the composition

KR1020150071539A 2015-05-22 2015-05-22 A composition of plants extract for treating atopic dermatitis KR20160137035A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150071539A KR20160137035A (en) 2015-05-22 2015-05-22 A composition of plants extract for treating atopic dermatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150071539A KR20160137035A (en) 2015-05-22 2015-05-22 A composition of plants extract for treating atopic dermatitis

Publications (1)

Publication Number Publication Date
KR20160137035A true KR20160137035A (en) 2016-11-30

Family

ID=57707564

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150071539A KR20160137035A (en) 2015-05-22 2015-05-22 A composition of plants extract for treating atopic dermatitis

Country Status (1)

Country Link
KR (1) KR20160137035A (en)

Similar Documents

Publication Publication Date Title
RU2671492C2 (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
KR100772575B1 (en) External composition for improvement of skin containing herbal extracts
KR101878069B1 (en) Composition comprising herbal mixture extracts and hinoki oil for preventing or treating acne and atopic dermatitis
EP3393488B1 (en) Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus
WO2019231050A1 (en) Cosmetic composition for hydrating skin and alleviating pruritus
KR102292975B1 (en) Cosmetic materials composition for skin anti-wrinkling and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof
KR101917645B1 (en) Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract
KR20160137040A (en) A composition of plants extract for treating atopic dermatitis
KR101220903B1 (en) Composition of skin external for improving of skin wrinkle
KR20210018388A (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
KR100530843B1 (en) Anti-inflammatory composition containing paecilomyces extract and cordyceps extracts as effective composition
EP3677264A1 (en) Composition for preventing or treating atopic dermatitis
CN104958228A (en) Whitening and freckle-removing composite preparation and preparation method thereof
KR20160137035A (en) A composition of plants extract for treating atopic dermatitis
JP5047511B2 (en) Granulocyte / macrophage colony stimulating factor (GM-CSF) production inhibitor I
KR102147641B1 (en) Cosmetic Composition for Improving Atopic Dermatitis with the Extract of Pyracantha fortuneana
KR20160020038A (en) Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil
KR102677418B1 (en) Active ingredient complex for alleviating skin irritation comprising high concentration of active ingredient
KR102503612B1 (en) Skin external composition
KR102282246B1 (en) Composition for preventing, alleviating, or treating atopic dermatitis
JP2012206961A (en) Antibacterial agent and skin external preparation
KR20240015188A (en) Composition to relieve pruritus and to recover skin barrier
KR20160123592A (en) A composition of plants extract for atopic dermatitis
KR20160133044A (en) Composition for protecting and treating atopic dermatitis comprising chlorin e6 having an improved stability
KR20240040207A (en) Active ingredient complex for alleviating skin irritation comprising high concentration of active ingredient

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application